Efficacy and common side effects of Trelagliptin

Trelagliptin (Trelagliptin) is a DPP-4 inhibitor that is widely used in the treatment of diabetes , especially for patients with type 2 diabetes. Its main mechanism of action is by inhibiting dipeptidyl peptidase-IV (DPP-4), thereby prolonging the half-life of **GLP-1 (glucagon-like peptide-1)**, promoting insulin secretion, and inhibiting glucagon release. In this way, trotagliptin helps lower blood sugar levels, especially in post-meal blood sugar control, and can effectively help diabetic patients maintain a more stable blood sugar state.

In clinical application, the efficacy of trolagliptin is mainly reflected in its ability to improve blood sugar control in diabetic patients, especially the control of postprandial blood sugar. As an oral hypoglycemic drug, trotagliptin is usually taken once a week, so patients have better compliance and reduce the burden of taking traditional drugs multiple times a day. In addition, trotagliptin also has good long-term efficacy, can continuously maintain blood sugar levels and reduce the risk of diabetic complications.

Although trotagliptin is effective in reducing diabetes, it may also cause some common side effects. The most common side effects include nasopharyngitis, upper respiratory tract infection, and rash. These side effects are usually mild and do not have a serious impact on the patient's quality of life. In addition, individual patients may experience headache, nausea, or gastrointestinal discomfort, but these symptoms usually decrease with time of use.

For patients taking trotagliptin for a long time, the most concerning thing is the possible hypoglycemic reaction. Although trotagliptin is unlikely to cause hypoglycemia on its own, caution should be exercised if used in combination with other antidiabetic drugs (such as insulin or sulfonylureas). In this case, patients should monitor their blood sugar levels regularly and adjust their treatment regimen as needed.

Reference materials:https://en.wikipedia.org/wiki/Trelagliptin